Findings about tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonist for the treatment of obesity, were presented at ObesityWeek. The study found consistent weight loss regardless of individual factors such as BMI, age, and various comorbidities. This is exciting news for those searching for medical weight loss options, as tirzepatide has shown promise as a useful treatment.
- About
- Medical Weight Loss
- Aging
- Hormone Optimization
- Peptide Therapy
- Sexual Health
- Health Testing